US health authorities to set targets for lowering drug prices

The U.S. Department of Health and Human Services is moving forward with a plan to peg U.S. drug prices to the lowest prices paid by other high-income OECD nations, following a Trump-era executive order aimed at lowering branded medicine costs; the move targets countries with a GDP per capita at least 60% of the U.S.'s, potentially leading to price cuts between 59% and 90%. Analysts anticipate legal challenges and implementation difficulties, suggesting the policy may be a negotiating tactic to raise international prices rather than a genuine effort to reduce U.S. pharma profits, while industry groups warn of stifled R&D and innovation. If implemented, it could cause prices to rise in countries within the 60% cutoff like Germany and Canada.

Analysis

The U.S. Department of Health and Human Services (HHS) has announced intentions to implement a 'most-favored-nation' (MFN) drug pricing policy, aiming to align U.S. prescription drug prices with the lowest levels paid by other high-income OECD countries. This policy, stemming from a Trump-era executive order, targets nations with a gross domestic product per capita of at least 60% of U.S. per-capita GDP and seeks price reductions between 59% and 90%. Despite the administration's stated commitment, underscored by Health Secretary Robert F. Kennedy Jr., Wall Street analysts express skepticism regarding the feasibility of implementation, citing anticipated legal challenges and a lack of detailed plans. BMO Capital Markets analyst Evan Seigerman views the move primarily as a strategic negotiating tactic to pressure for higher international prices rather than a direct assault on U.S. pharmaceutical profits. The pharmaceutical sector has already experienced negative sentiment, with the SPDR S&P Pharmaceutical ETF declining nearly 5% year-to-date in 2025, reflecting investor concerns over potential policy impacts on financial outlooks for companies like AbbVie, Amgen, and Pfizer, all of which exhibit negative sentiment signals. The industry, represented by PhRMA, argues that such price controls would stifle research and development and that the focus should be on middlemen and international free-riding. Georgetown's McDonough School of Business assistant professor Yunan Ji highlights that implementing such a policy in the U.S., the largest prescription drug market, could disrupt the 'global equilibrium,' forcing contract renegotiations and potentially increasing prices in other developed nations like Germany and Canada. The overall tone surrounding this development is uncertain, reflecting the significant hurdles to actualizing these price cuts.

Key Decisions for Investors

• Investors should maintain a cautious stance on pharmaceutical stocks, particularly those with significant U.S. market exposure such as ABBV, AMGN, and PFE, given the announced MFN policy's potential to drastically reduce prices, despite current implementation uncertainties and expected legal opposition.
• Monitor upcoming HHS announcements regarding specific price targets for manufacturers and the progress of negotiations, as these will serve as critical catalysts influencing sector sentiment and individual stock performance.
• Consider the heightened regulatory risk and potential for increased share price volatility within the healthcare sector, and be prepared for a protracted period of negotiation and legal battles which may delay or alter the ultimate impact of the proposed pricing reforms.
• Evaluate the possibility that the MFN policy, as suggested by some analysts, may be a leveraging tool for broader international pricing discussions rather than an immediate, drastic profit squeeze, which could present tactical opportunities based on evolving news flow and actual implementation timelines.